Long circulating lipid nanocapsules for drug detoxification

Biomaterials

Volumn 28, Issue 6, 2007, Pages 1248-1257

  Babu Dhanikula, Anand ^a   Mohamed Khalid, Nabil ^a   Lee, Stephen D ^b   Yeung, Rosanna ^b   Risovic, Verica ^b   Wasan, Kishor M ^b   Leroux, Jean Christophe ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Detoxification; Haloperidol; Lipoprotein distribution; Nanocapsule; Taxanes; Uptake

Indexed keywords

DETOXIFICATION; FATTY ACIDS; LIPIDS; MATHEMATICAL MODELS; NANOSTRUCTURED MATERIALS; POLYETHYLENE GLYCOLS; PROTEINS;

DOCETAXEL; DRUG MODELS; HALOPERIDOL; LIPOPROTEIN DISTRIBUTION; NANOCAPSULES (NC); TAXANES;

DRUG PRODUCTS;

DOCETAXEL; FATTY ACID; HALOPERIDOL; LIPID NANOCAPSULE; LIPOPROTEIN; MACROGOL; MEDIUM CHAIN TRIACYLGLYCEROL; NANOCAPSULE; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLOID; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DETOXIFICATION; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIPOPROTEIN BLOOD LEVEL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANIMALS; CAPSULES; DIFFUSION; DRUG CARRIERS; LIPIDS; MALE; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; MICE; NANOSTRUCTURES; ORGAN SPECIFICITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 33751341130     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2006.10.036     Document Type: Article

References (45)

1. Herrington A.M., and Clifton G.D. Toxicology and management of acute drug ingestions in adults. Pharmacotherapy 15 (1995) 182-200
2. Vernon D.D., and Gleich M.C. Poisoning and drug overdose. Crit Care Clin 13 (1997) 647-667
3. Mokhlesi B., Leikin J.B., Murray P., and Corbridge T.C. Adult toxicology in critical care: part I: general approach to the intoxicated patient. Chest 123 (2003) 577-592
4. Haydon E., Rehm J., Fischer B., Monga N., and Adlaf E. Prescription drug abuse in Canada and the diversion of prescription drugs into the illicit drug market. Can J Public Health 96 (2005) 459-461
5. Greene S.L., Dargan P.I., and Jones A.L. Acute poisoning: understanding 90% of cases in a nutshell. Postgrad Med J 81 (2005) 204-216
6. Gunnell D., Ho D., and Murray V. Medical management of deliberate drug overdose: a neglected area for suicide prevention?. Emerg Med J 21 (2004) 35-38
7. Single E., Robson L., Rehm J., and Xie X. Morbidity and mortality attributable to alcohol, tobacco and illicit drug use in Canada. Am J Public Health 89 (1999) 385-390
8. Litovitz T.L., Smilkstein M., Felberg L., Klein-Schwartz W., Berlin R., and Morgan J. 199 Annual report of the american association of poison control centers toxic exposure surveillance system. Am J Emerg Med 15 (1997) 447-500
9. CDC. Increase in poisoning deaths caused by non-illicit drugs-Utah, 1991-2003. MMWR 293 (2005) 1182-1183
10. Deo N., Somasundaran T., and Somasundaran P. Solution properties of amitriptyline and its partitioning into lipid bilayers. Coll Surf B Biointerfaces 34 (2004) 155-159
11. Chyka P.A., and Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 35 (1997) 721-741
12. Merigian K.S., and Blaho K. Diagnosis and management of the drug overdose patient. Am J Ther 4 (1997) 99-113
13. Underhill R., Jovanovic A., Carino S., Varhney M., Shah D., Dennis D., et al. Oil-filled silica nanocapsules for lipophilic drug uptake: implications for drug detoxification therapy. Chem Mater 14 (2002) 4919-4925
14. Lee D., Flint J., Morey T., Dennis D., Partch R., and Baney R. Aromatic-aromatic interaction of amitriptyline: implication of overdosed drug detoxification. J Pharm Sci 94 (2005) 373-381
15. Fallon M.S., and Chauhan A. Sequestration of amitriptyline by liposomes. J Colloid Interface Sci 300 (2006) 7-19
16. Traul K.A., Driedger A., Ingle D.L., and Nakhasi D. Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol 38 (2000) 79-98
17. Asher W.J., Bovee K.C., Frankenfeld J.W., Hamilton R.W., Henderson L.W., Holtzapple P.G., et al. Liquid membrane system directed toward chronic uremia. Kidney Int 7 Suppl. (1975) 409-412
18. Frankenfeld J.W., Fuller G.C., and Rhodes C.T. Potential use of liquid membranes for emergency treatment of drug overdose. Drug Dev Commun 2 (1976) 405-419
19. Morimoto Y., Sugibayashi K., Yamaguchi Y., and Kato Y. Detoxication capacity of a multiple (w/o/w) emulsion for the treatment of drug overdose: drug extraction into the emulsion in the gastro-intestinal tract of rabbits. Chem Pharm Bull (Tokyo) 27 (1979) 3188-3192
20. Weinberg G., Ripper R., Feinstein D.L., and Hoffman W. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med 28 (2003) 198-202
21. Yoav G., Odelia G., and Shaltiel C. A lipid emulsion reduces mortality from clomipramine overdose in rats. Vet Hum Toxicol 44 (2002) 30
22. Tebbutt S., Harvey M., Nicholson T., and Cave G. Intralipid prolongs survival in a rat model of verapamil toxicity. Acad Emerg Med 13 (2006) 134-139
23. Rollins C.J. Total nutrient admixtures: stability issues and their impact on nursing practice. J Intraven Nurs 20 (1997) 299-304
24. Vilaro S., and Llobera M. Uptake and metabolism of Intralipid by rat liver: an electron-microscopic study. J Nutr 118 (1988) 932-940
25. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 875 (2002) 875-880
26. Froemming J.S., Lam Y.W., Jann M.W., and Davis C.M. Pharmacokinetics of haloperidol. Clin Pharmacokinet 17 (1989) 396-423
27. Darby J.K., Pasta D.J., Dabiri L., Clark L., and Mosbacher D. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 15 (1995) 334-340
28. Kudo S., and Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 37 (1999) 435-456
29. Levine B.S., Wu S.C., Goldberger B.A., and Caplan Y.H. Two fatalities involving haloperidol. J Anal Toxicol 15 (1991) 282-284
30. Yoshida I., Sakaguchi Y., Matsuishi T., Yano E., Yamashita Y., Hayata S., et al. Acute accidental overdosage of haloperidol in children. Acta Paediatr 82 (1993) 877-880
31. Hansen L.M., Megerian G., and Donnenfeld A.E. Haloperidol overdose during pregnancy. Obstet Gynecol 90 (1997) 659-661
32. Kan P., Chen Z.B., Lee C.J., and Chu I.M. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J Control Release 58 (1999) 271-278
33. Khalid M.N., Simard P., Hoarau D., Dragomir A., and Leroux J.C. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res 23 (2006) 752-758
34. Hoarau D., Delmas P., David S., Roux E., and Leroux J.C. Novel long-circulating lipid nanocapsules. Pharm Res 21 (2004) 1783-1789
35. Wasan K.M., Pritchard P.H., Ramaswamy M., Wong W., Donnachie E.M., and Brunner L.J. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm Res 14 (1997) 1613-1620
36. Rossignol D.P., Wasan K.M., Choo E., Yau E., Wong N., Rose J., et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother 48 (2004) 3233-3240
37. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
38. Mosqueira V.C., Legrand P., Morgat J.L., Vert M., Mysiakine E., Gref R., et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res 18 (2001) 1411-1419
39. Lamprecht A., Bouligand Y., and Benoit J.P. New lipid nanocapsules exhibit sustained release properties for amiodarone. J Control Release 84 (2002) 59-68
40. Wretlind A. The toxicity of low-molecular triglycerides. Acta Physiol Scand 40 (1957) 338-343
41. Radd B.L., Newman A.C., Fegely B.J., Chrzanowski F.A., Lichten J.L., and Walkling W.D. Development of haloperidol in oil injection formulations. J Parenter Sci Technol 39 (1985) 48-51
42. Leroux J.C., De Jaeghere F., Anner B., Doelker E., and Gurny R. An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(d,l-lactic acid) nanoparticles by human monocytes. Life Sci 57 (1995) 695-703
43. Moghimi S.M., and Hunter A.C. Capture of stealth nanoparticles by the body's defences. Crit Rev Ther Drug Carrier Syst 18 (2001) 527-550
44. Ueda K., Ishida M., Inoue T., Fujimoto M., Kawahara Y., Sakaeda T., et al. Effect of injection volume on the pharmacokinetics of oil particles and incorporated menatetrenone after intravenous injection as O/W lipid emulsions in rats. J Drug Target 9 (2001) 353-360
45. Folger W.E., Wade R., Brundish D.E., and Fidler I.J. Distribution and fate of free and liposome-encapsulated [3H] Nor-muramyl dipeptide and [3H] muramyl tripeptide phosphatidylethanolamine in mice. J Immunol 135 (1985) 1372-1377